High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence.
The prevalence of hepatitis C virus (HCV) infection was evaluated in 227 hemodialysis patients from four units in Caracas, Venezuela, by using different second- and third-generation enzyme immunoassays (EIAs) and immunoblot assays. HCV antibodies were detected in 162 patients (71%) by the recombinant-based second-generation assays (Abbott and Ortho) and in 161 patients by the synthetic peptide-based EIA (UBI). Of the 162 HCV antibody-positive serum samples, 161 were confirmed to be positive by RIBA 3. HCV RNA was detected in 49 of 68 (72%) of the seropositive patients and in 5 of 21 (24%) of the seronegative ones. HCV RNA was not always correlated with an increase in alanine aminotransferase (ALT) levels. Among 20 patients positive for HCV RNA and for HCV antibodies (without any hepatitis B virus [HBV] marker), only 10 had elevated ALT levels. The possible interference of HBV for HCV replication was evaluated. No significant difference was found between the presence of HCV RNA and the presence of any HBV serological markers. The possible routes of transmission of HCV in hemodialysis patients are multiple, and some of them are still controversial. Of the HCV-positive patients, 30% received a blood transfusion, significantly more than the 15% found for the HCV-negative group. However, blood transfusions alone could not account for the high incidence observed in this group of patients (38% from 1994 to 1995). In conclusion, about one-quarter of the apparently non-HCV-infected patients were probably seroconverting, ALT may not be a useful indicator of HCV infection in hemodialysis patients, and nosocomial transmission of HCV may play a role in the spread of HCV in this group.
Pujol
F H
FH
Lab Biología de Virus, Instituto Venezolano de Investigaciones Cientifican, Caracas, Venezuela. fpujol@pasteur.ivic.ve
Ponce
J G
JG
Lema
M G
MG
Capriles
F
F
Devesa
M
M
Sirit
F
F
Salazar
M
M
Vásquez
G
G
Monsalve
F
F
Blitz-Dorfman
L
L
D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers; D003428:Cross Infection / Q000453:epidemiology / Q000276:immunology / Q000635:transmission; D006436:Hemodialysis Units, Hospital; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000453:epidemiology* / Q000276:immunology / Q000635:transmission*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D065227:Transfusion Reaction; D014687:Venezuela / Q000453:epidemiology
D015415:Biomarkers; D018937:Hepatitis C Antibodies; D012367:RNA, Viral; D000410:Alanine Transaminase